Related Experiment Video

Updated: Apr 20, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K

Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor

Lingyun Qin1, Fei Yang, Cindy Zhou

  • 1Department of Biotechnology and Collaborative Innovation Center for Industrial Fermentation, Hubei University of Technology , Wuhan 430068, China.

Journal of the American Chemical Society
|December 3, 2014
PubMed

Insights

A new dual small-molecule drug effectively reactivates the p53 pathway by targeting Mdm2/MdmX in cancer cells. This approach offers a promising therapeutic strategy for cancers overexpressing these proteins.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Aberrant p53-Mdm2/MdmX interactions impair p53 function in ~50% of human cancers.
  • Overexpression of Mdm2 and/or MdmX is a common mechanism for p53 inactivation in cancer.
  • Inhibiting both Mdm2 and MdmX shows greater efficacy in promoting cancer cell apoptosis than single-target inhibition.

Purpose of the Study:

  • To develop and validate a dual small-molecule antagonist targeting both Mdm2 and MdmX.
  • To assess the efficacy of this dual antagonist in reactivating the p53 pathway in cancer models.
  • To establish a potential therapeutic candidate for cancers with Mdm2/MdmX overexpression.

Main Methods:

  • Rational drug design based on segmental mutational analysis of MdmX.
  • Utilizing the crystal structure of the Mdm2 N-terminal domain complexed with nutlin-3a.
  • Testing the dual antagonist in cancer cell models overexpressing MdmX and/or Mdm2.

Main Results:

  • The dual small-molecule antagonist efficiently reactivated the p53 pathway.
  • Demonstrated efficacy in model cancer cells overexpressing MdmX and/or Mdm2.
  • Established a viable small molecule therapeutic candidate.

Conclusions:

  • Dual inhibition of Mdm2 and MdmX is a potent strategy for cancer therapy.
  • The developed dual antagonist is a promising therapeutic candidate for Mdm2/MdmX-overexpressing cancers.
  • This study validates a novel approach to targeting the p53-Mdm2/MdmX axis in oncology.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

2.2K
Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.4K